Boehringer Ingelheim Renews Global SRS License
News May 22, 2006
SRS has been in use at Boehringer Ingelheim for the past 5 years and is an integral part of its Bioinformatics platform.
As part of the renewal agreement BioWisdom SRS will be responsible for upgrading the Biberach (Germany) and Ridgefield (USA) sites to new versions of the software.
"Renewing customers is the best endorsement for the SRS product," said Gordon Smith Baxter, CEO of BioWisdom.
"Feedback from long term customers, such as Boehringer Ingelheim, is essential for the SRS team to continue to provide software with a strong value proposition and we are pleased to be working with them for another year."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.